106 related articles for article (PubMed ID: 30968715)
1. PCC0208018 exerts antitumor effects by activating effector T cells.
Ge M; Hu Z; Chen X; Du G; Wang H; Liu R; Ye L; Tian J
Int J Immunopathol Pharmacol; 2019; 33():2058738419843366. PubMed ID: 30968715
[TBL] [Abstract][Full Text] [Related]
2. PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice.
Hu Z; Yu P; Du G; Wang W; Zhu H; Li N; Zhao H; Dong Z; Ye L; Tian J
PLoS One; 2020; 15(3):e0228339. PubMed ID: 32214351
[TBL] [Abstract][Full Text] [Related]
3. Combined SEP and anti-PD-L1 antibody produces a synergistic antitumor effect in B16-F10 melanoma-bearing mice.
Hu Z; Ye L; Xing Y; Hu J; Xi T
Sci Rep; 2018 Jan; 8(1):217. PubMed ID: 29317734
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model.
Meng X; Du G; Ye L; Sun S; Liu Q; Wang H; Wang W; Wu Z; Tian J
Int J Immunopathol Pharmacol; 2017 Sep; 30(3):215-226. PubMed ID: 28604143
[TBL] [Abstract][Full Text] [Related]
5. An engineered PD-1-based and MMP-2/9-oriented fusion protein exerts potent antitumor effects against melanoma.
Wei M; Liu X; Cao C; Yang J; Lv Y; Huang J; Wang Y; Qin Y
BMB Rep; 2018 Nov; 51(11):572-577. PubMed ID: 30021673
[TBL] [Abstract][Full Text] [Related]
6. Novel Treatment of Melanoma: Combined Parasite-Derived Peptide GK-1 and Anti-Programmed Death Ligand 1 Therapy.
Vera-Aguilera J; Perez-Torres A; Beltran D; Villanueva-Ramos C; Wachtel M; Moreno-Aguilera E; Vera-Aguilera C; Ventolini G; Martínez-Zaguilán R; Sennoune SR
Cancer Biother Radiopharm; 2017 Mar; 32(2):49-56. PubMed ID: 28301259
[TBL] [Abstract][Full Text] [Related]
7. Ilexgenin A induces B16-F10 melanoma cell G1/S arrest in vitro and reduces tumor growth in vivo.
Yang H; Liu C; Zhang YQ; Ge LT; Chen J; Jia XQ; Gu RX; Sun Y; Sun WD
Int Immunopharmacol; 2015 Feb; 24(2):423-431. PubMed ID: 25596038
[TBL] [Abstract][Full Text] [Related]
8. Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8
Yin W; Song Y; Liu Q; Wu Y; He R
Immunology; 2017 Oct; 152(2):287-297. PubMed ID: 28556970
[TBL] [Abstract][Full Text] [Related]
9. Programmed Cell Death Protein Ligand-1 Silencing with Polyethylenimine-Dermatan Sulfate Complex for Dual Inhibition of Melanoma Growth.
Kwak G; Kim D; Nam GH; Wang SY; Kim IS; Kim SH; Kwon IC; Yeo Y
ACS Nano; 2017 Oct; 11(10):10135-10146. PubMed ID: 28985469
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.
Marshall NA; Galvin KC; Corcoran AM; Boon L; Higgs R; Mills KH
Cancer Res; 2012 Feb; 72(3):581-91. PubMed ID: 22158905
[TBL] [Abstract][Full Text] [Related]
11. Nicotinamide inhibits melanoma in vitro and in vivo.
Scatozza F; Moschella F; D'Arcangelo D; Rossi S; Tabolacci C; Giampietri C; Proietti E; Facchiano F; Facchiano A
J Exp Clin Cancer Res; 2020 Oct; 39(1):211. PubMed ID: 33028392
[TBL] [Abstract][Full Text] [Related]
12. Soluble form of T cell Ig mucin 3 is an inhibitory molecule in T cell-mediated immune response.
Geng H; Zhang GM; Li D; Zhang H; Yuan Y; Zhu HG; Xiao H; Han LF; Feng ZH
J Immunol; 2006 Feb; 176(3):1411-20. PubMed ID: 16424168
[TBL] [Abstract][Full Text] [Related]
13. T-Cell-Specific Loss of the PI-3-Kinase p110α Catalytic Subunit Results in Enhanced Cytokine Production and Antitumor Response.
Aragoneses-Fenoll L; Ojeda G; Montes-Casado M; Acosta-Ampudia Y; Dianzani U; Portolés P; Rojo JM
Front Immunol; 2018; 9():332. PubMed ID: 29535720
[TBL] [Abstract][Full Text] [Related]
14. [Interleukin-12 restores and promotes the T-cell immune function inhibited by 5-fluorouracil].
Chi PD; Li L; Fan YY; Wu CY
Ai Zheng; 2007 Aug; 26(8):801-8. PubMed ID: 17697537
[TBL] [Abstract][Full Text] [Related]
15. Acid-Activatable Versatile Micelleplexes for PD-L1 Blockade-Enhanced Cancer Photodynamic Immunotherapy.
Wang D; Wang T; Liu J; Yu H; Jiao S; Feng B; Zhou F; Fu Y; Yin Q; Zhang P; Zhang Z; Zhou Z; Li Y
Nano Lett; 2016 Sep; 16(9):5503-13. PubMed ID: 27525587
[TBL] [Abstract][Full Text] [Related]
16. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
17. Axitinib, a selective inhibitor of vascular endothelial growth factor receptor, exerts an anticancer effect in melanoma through promoting antitumor immunity.
Zhang X; Fang X; Gao Z; Chen W; Tao F; Cai P; Yuan H; Shu Y; Xu Q; Sun Y; Gu Y
Anticancer Drugs; 2014 Feb; 25(2):204-11. PubMed ID: 24135499
[TBL] [Abstract][Full Text] [Related]
18. The heat shock protein 90 inhibitor SNX-2112 inhibits B16 melanoma cell growth in vitro and in vivo.
Liu KS; Ding WC; Wang SX; Liu Z; Xing GW; Wang Y; Wang YF
Oncol Rep; 2012 Jun; 27(6):1904-10. PubMed ID: 22447251
[TBL] [Abstract][Full Text] [Related]
19. CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells.
Appleman LJ; van Puijenbroek AA; Shu KM; Nadler LM; Boussiotis VA
J Immunol; 2002 Mar; 168(6):2729-36. PubMed ID: 11884439
[TBL] [Abstract][Full Text] [Related]
20. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
